558 related articles for article (PubMed ID: 11280786)
21. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
22. HuR-mediated control of C/EBPbeta mRNA stability and translation in ALK-positive anaplastic large cell lymphomas.
Bergalet J; Fawal M; Lopez C; Desjobert C; Lamant L; Delsol G; Morello D; Espinos E
Mol Cancer Res; 2011 Apr; 9(4):485-96. PubMed ID: 21343335
[TBL] [Abstract][Full Text] [Related]
23. Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells.
Shelton JG; Steelman LS; Lee JT; Knapp SL; Blalock WL; Moye PW; Franklin RA; Pohnert SC; Mirza AM; McMahon M; McCubrey JA
Oncogene; 2003 Apr; 22(16):2478-92. PubMed ID: 12717425
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
[TBL] [Abstract][Full Text] [Related]
25. Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA).
Ouyang T; Bai RY; Bassermann F; von Klitzing C; Klumpen S; Miething C; Morris SW; Peschel C; Duyster J
J Biol Chem; 2003 Aug; 278(32):30028-36. PubMed ID: 12748172
[TBL] [Abstract][Full Text] [Related]
26. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
27. Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells.
Armstrong F; Duplantier MM; Trempat P; Hieblot C; Lamant L; Espinos E; Racaud-Sultan C; Allouche M; Campo E; Delsol G; Touriol C
Oncogene; 2004 Aug; 23(36):6071-82. PubMed ID: 15208656
[TBL] [Abstract][Full Text] [Related]
28. ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors.
Lu L; Ghose AK; Quail MR; Albom MS; Durkin JT; Holskin BP; Angeles TS; Meyer SL; Ruggeri BA; Cheng M
Biochemistry; 2009 Apr; 48(16):3600-9. PubMed ID: 19249873
[TBL] [Abstract][Full Text] [Related]
29. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
[TBL] [Abstract][Full Text] [Related]
30. Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.
Bohling SD; Jenson SD; Crockett DK; Schumacher JA; Elenitoba-Johnson KS; Lim MS
Leuk Res; 2008 Mar; 32(3):383-93. PubMed ID: 17720243
[TBL] [Abstract][Full Text] [Related]
31. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase.
Turner SD; Tooze R; Maclennan K; Alexander DR
Oncogene; 2003 Oct; 22(49):7750-61. PubMed ID: 14586401
[TBL] [Abstract][Full Text] [Related]
32. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target.
Chiarle R; Simmons WJ; Cai H; Dhall G; Zamo A; Raz R; Karras JG; Levy DE; Inghirami G
Nat Med; 2005 Jun; 11(6):623-9. PubMed ID: 15895073
[TBL] [Abstract][Full Text] [Related]
33. Serine phosphorylation of NPM-ALK, which is dependent on the auto-activation of the kinase activation loop, contributes to its oncogenic potential.
Wang P; Wu F; Zhang J; McMullen T; Young LC; Ingham RJ; Li L; Lai R
Carcinogenesis; 2011 Feb; 32(2):146-53. PubMed ID: 21045017
[TBL] [Abstract][Full Text] [Related]
34. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B.
Montaner S; Sodhi A; Pece S; Mesri EA; Gutkind JS
Cancer Res; 2001 Mar; 61(6):2641-8. PubMed ID: 11289142
[TBL] [Abstract][Full Text] [Related]
35. Truncated ALK derived from chromosomal translocation t(2;5)(p23;q35) binds to the SH3 domain of p85-PI3K.
Polgar D; Leisser C; Maier S; Strasser S; Rüger B; Dettke M; Khorchide M; Simonitsch I; Cerni C; Krupitza G
Mutat Res; 2005 Feb; 570(1):9-15. PubMed ID: 15680399
[TBL] [Abstract][Full Text] [Related]
36. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum.
Falini B; Bigerna B; Fizzotti M; Pulford K; Pileri SA; Delsol G; Carbone A; Paulli M; Magrini U; Menestrina F; Giardini R; Pilotti S; Mezzelani A; Ugolini B; Billi M; Pucciarini A; Pacini R; Pelicci PG; Flenghi L
Am J Pathol; 1998 Sep; 153(3):875-86. PubMed ID: 9736036
[TBL] [Abstract][Full Text] [Related]
37. Interferon-dependent activation of the serine kinase PI 3'-kinase requires engagement of the IRS pathway but not the Stat pathway.
Uddin S; Majchrzak B; Wang PC; Modi S; Khan MK; Fish EN; Platanias LC
Biochem Biophys Res Commun; 2000 Apr; 270(1):158-62. PubMed ID: 10733921
[TBL] [Abstract][Full Text] [Related]
38. Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas.
Jäger R; Hahne J; Jacob A; Egert A; Schenkel J; Wernert N; Schorle H; Wellmann A
Anticancer Res; 2005; 25(5):3191-6. PubMed ID: 16101126
[TBL] [Abstract][Full Text] [Related]
39. Phosphoinositide-3 kinase-PKB/Akt pathway activation is involved in fibroblast Rat-1 transformation by human T-cell leukemia virus type I tax.
Liu Y; Wang Y; Yamakuchi M; Masuda S; Tokioka T; Yamaoka S; Maruyama I; Kitajima I
Oncogene; 2001 May; 20(20):2514-26. PubMed ID: 11420661
[TBL] [Abstract][Full Text] [Related]
40. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma.
Trinei M; Lanfrancone L; Campo E; Pulford K; Mason DY; Pelicci PG; Falini B
Cancer Res; 2000 Feb; 60(4):793-8. PubMed ID: 10706082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
